• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.13% Nasdaq Up0.70%

    Isis Pharmaceuticals, Inc. (ISIS)

    -NasdaqGS
    63.65 Up 4.16(6.99%) Dec 26, 4:00PM EST
    |After Hours : 63.74 Up 0.09 (0.14%) Dec 26, 7:55PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Isis Pharmaceuticals, Inc.
    2855 Gazelle Court
    Carlsbad, CA 92010
    United States - Map
    Phone: 760-931-9200
    Website: http://www.isispharm.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Drug Manufacturers - Other
    Full Time Employees:365

    Business Summary 

    Isis Pharmaceuticals, Inc. is engaged in the discovery and development of antisense drugs using novel drug discovery platform. The company’s flagship product includes the KYNAMRO injection, which is an apo-B synthesis inhibitor for patients with homozygous familial hypercholesterolemia; and for the reduction of low-density lipoprotein cholesterol. It also has a pipeline of 31 drugs in development for the treatment of various diseases, including cardiovascular and metabolic diseases; severe and rare diseases, including neurological disorders; and cancer. The company has strategic alliances and collaboration agreements primarily with AstraZeneca AB, Biogen Idec MA Inc., Bristol-Myers Squibb, Eli Lilly and Company, Genzyme Corporation, GlaxoSmithKline, Hoffman-La Roche Inc., F. Hoffmann-La Roche Ltd., Alnylam Pharmaceuticals, Inc., Antisense Therapeutics Limited, Excaliard Pharmaceuticals, Inc., iCo Therapeutics Inc., OncoGenex Technologies Inc., and Xenon Pharmaceuticals Inc. Isis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Isis Pharmaceuticals, Inc.

    Corporate Governance 
    Isis Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Dec 1, 2014 is 5. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 6; Compensation: 5.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Dr. Stanley T. Crooke M.D., Ph.D., 69
    Founder, Exec. Chairman, Chief Exec. Officer, Pres, Chairman of Science/Medical Committee and Member of Agenda Committee
    1.55M9.27M
    Ms. Elizabeth L. Hougen , 52
    Chief Financial Officer, Principal Accounting Officer and Sr. VP of Fin.
    601.00K340.00K
    Ms. B. Lynne Parshall Esq., J.D., 60
    Chief Operating Officer, Corp. Sec., Director and Member of Agenda Committee
    1.19M7.64M
    Dr. C. Frank Bennett BSc, Ph.D., 57
    Sr. VP of Antisense Research
    651.00K1.37M
    Dr. Richard S. Geary Ph.D., 56
    Sr. VP of Devel.
    639.00K1.98M
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders